Form 4: PTC Therapeutics Executive VP and CLO, Mark Elliott Boulding, Executes Stock Transactions Under 10b5-1 Plan

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, engaged in multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Elliott Boulding, an Executive VP and CLO at PTC Therapeutics, executed several transactions involving the company's common stock.
• These transactions occurred on December 2nd and 3rd, 2024, and included both the acquisition of shares through option exercises and the sale of shares.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on October 31, 2023.
• On December 2nd, Boulding exercised options to acquire 1,960 shares at $51 each and sold the same amount at an average price of $52.17.
• Also on December 2nd, he exercised options for 83,640 shares at $51 each and sold the same amount at an average price of $52.26.
• On December 3rd, Boulding exercised options to acquire 600 shares at $33.02 each and sold the same amount at an average price of $53.04.
• Further on December 3rd, he exercised options for 7,720 shares at $33.02 each and sold 6,315 shares at an average price of $53.14 and 1,405 shares at an average price of $54.05.
• Additionally on December 3rd, he exercised options for 1,988 shares at $33.02 each and sold 1,900 shares at an average price of $53.13 and 88 shares at an average price of $54.14.
• The prices for the sales represent weighted average prices from multiple trades within specified ranges.
• Following these transactions, Boulding's direct ownership of PTC Therapeutics common stock is 92,389 shares.

Sentiment

Score: 5

Explanation: The document reflects routine stock transactions by an executive under a pre-arranged plan. It is neither particularly positive nor negative.

Positives

• The transactions were conducted under a pre-established 10b5-1 trading plan, which is a common practice for corporate insiders to avoid accusations of insider trading.
• The exercise of stock options indicates a belief in the company's long-term value by the executive.

Negatives

• The sale of shares by an executive could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react negatively to the sale of shares by a company executive, even if it is part of a pre-planned trading strategy.
• Fluctuations in the stock price could impact the value of the remaining shares held by the executive.

Industry Context

This type of filing is standard for corporate insiders who engage in stock transactions. The use of a 10b5-1 plan is a common practice to avoid insider trading concerns.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like PTC Therapeutics.
• Similar filings are regularly made by executives at companies like BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals, when they execute stock transactions.
• The reported transaction prices are within the typical range for stock sales by executives, reflecting market conditions at the time of the transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial position.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

PTC Therapeutics, Stock Transactions, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Executive Compensation, Share Sales